ABT Stock Analysis: Buy, Sell, or Hold?
ABT - Abbott Laboratories
$84.90
1.07 (1.28%)
▲
5d:
-2.43%
30d:
-16.4%
90d:
-23.84%
HOLD
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: Jul 16, 2026
Smart Money Accumulation
None View Scanner →
Strength: 8.0/10
Get Alerted When ABT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
11 traders called ABT this week
69% bullish • 4 bearish
69% bullish • 4 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ABT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ABT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$158.51
Based on 7.3% avg growth
INTRINSIC VALUE TODAY
$98.42
13.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ABT is currently trading at $84.90, which is considered oversold relative to its 30-day fair value range of $86.47 to $99.50. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.0) compared to its historical average (18.4). Remarkably, the market is currently pricing in an annual earnings decline of 8.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ABT is in a strong downtrend. Immediate support is located at $81.97, while resistance sits at $91.00.
Market Sentiment: ABT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $118.64 (+39.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ABT is in a strong downtrend. Immediate support is located at $81.97, while resistance sits at $91.00.
Market Sentiment: ABT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $118.64 (+39.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$86.47 -
$99.50
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding ABT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 39.7% below Wall St target ($118.64)
Trading Range Analysis
30-Day Trading Range
$86.47 -
$99.50
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$81.97
Resistance Level
$91.00
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.00
Wall Street Target
$118.64
(+39.7%)
Revenue Growth (YoY)
7.8%
Earnings Growth (YoY)
-19.7%
Profit Margin
13.9%
Valuation Discount vs History
-8.8% cheaper
PE vs Historical
14.0 vs 18.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.8%
(market-implied from PE analysis)
1-Year Target
$77.43
(-9%)
2-Year Target
$70.62
(-17%)
3-Year Target
$64.40
(-24%)
3-Yr Target (if PE normalizes)
(PE: 14→18)
$84.64
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 10.6%)
$180.81
(+113%)
Base:
(SPY PE: 14.0, Growth: 10.6%)
$114.86
(+35%)
Bear:
(PE: 11.9, Growth: 10.6%)
$97.63
(+15%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (23x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 23.48 | Current EPS (TTM): $3.57
Bull Case
$156.63
(+85%)
Analyst growth 69.9%, PE expands to 25.8
Base Case
$142.39
(+68%)
Market implied 69.9%, PE stable at 23.5
Bear Case
$57.00
(-33%)
Severe decline -20.0%, PE contracts to 20.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.0 to 18.4
Stabilization Target:
$111.58
(+31.4%)
PE Expansion Potential:
+31.4%
Share & Embed Analysis
Last updated: May 14, 2026 7:27 PM ET
Data refreshes hourly during market hours. Next update: 8:27 PM
Data refreshes hourly during market hours. Next update: 8:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABT showing a specific setup today?
Insider Activity (6 Months)
7
Buys
13
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
SELL
2026-03-30
Laura Friedman
SELL
2026-03-24
Ro Khanna
BUY
2026-03-23
Featured in Portfolios
ABT is a key holding in these high-performance investment strategies.
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$85 | 55 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$392 | 62 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$84 | 60 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$108 | 62 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 52 HOLD |
Advanced ABT Option Strategies
Professional options setups generated by AI based on today's ABT price and gamma walls.
